logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Sionna Therapeutics Launches With $111 Million Series B Financing To Advance Pipeline Of Novel Small Molecules With The Potential To Fully Restore Cftr Function In Cystic Fibrosis

Apr 19, 2022•over 3 years ago

Amount Raised

$111 Million

Round Type

series b

Boston

Description

Sionna Therapeutics, a life sciences company founded in 2019 to develop highly effective and differentiated treatments for cystic fibrosis (CF), today announced the official launch of the company and the closing of a $111 million Series B financing. The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG's The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation. Sionna has raised approximately $150 million to date.

Company Information

Company

Sionna Therapeutics

Location

Boston, Massachusetts, United States

About

Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Building on over a decade of extensive research on the genetic mutations associated with CF and founded in 2019, Sionna is advancing a pipeline of small molecules engineered to correct ΔF508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs targeting correction of NBD1, the key and unique mechanism to enable full restoration of ΔF508-CFTR function, and complementary programs targeting ICL4 and TMD1 domains. Sionna's pipeline has the potential to deliver best-in-class efficacy and reach previously unachievable levels of long-term benefit for people with CF. For information about Sionna visit https://www.sionnatx.com/.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech